• Anthony E Pusateri, Richard B Weiskopf, Vikhyat Bebarta, Frank Butler, Ramon F Cestero, Irshad H Chaudry, Virgil Deal, Warren C Dorlac, Robert T Gerhardt, Michael B Given, Dan R Hansen, W Keith Hoots, Harvey G Klein, Victor W Macdonald, Kenneth L Mattox, Rodney A Michael, Jon Mogford, Elizabeth A Montcalm-Smith, Debra M Niemeyer, W Keith Prusaczyk, Joseph F Rappold, Todd Rassmussen, Francisco Rentas, James Ross, Christopher Thompson, Leo D Tucker, and US DoD Hemorrhage and Resuscitation Research and Development Steering Committee.
• US Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702, USA. anthony.pusateri@amedd.army.mil
• Shock. 2013 Feb 1;39(2):121-6.

AbstractA recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.

21 keywords...

hide…